CompanyNTHINasdaqCalabasas, CA

Neonc Technologies, Inc.

NeOnc Technologies is a clinical-stage company developing CNS therapeutics that cross the blood-brain barrier.

SEC EDGAR ClinicalTrials.gov neonc.com

8-KSep 28Latest SEC filing

Sep 28Latest story

September 2026

NeOnc to hold FDA meeting on NEO212 for glioma program

Sep 28Clinical readoutNEO212 Neonc Technologies, Inc.

NeOnc CEO buys more stock after positive NEO100 Phase 2a data

Sep 17Clinical readoutNeonc Technologies, Inc.perillyl alcohol

NeOnc prices $15 million registered direct offering of stock and warrants

Sep 10FinancingNeonc Technologies, Inc.

August 2026

NeOnc Technologies amends filing to add Shomali's audit committee role

Aug 21PeopleNeonc Technologies, Inc.

NeOnc reports Phase 2a NEO100-01 met primary endpoint in recurrent IDH1 mutant glioma

Aug 13PeopleNeonc Technologies, Inc.perillyl alcohol

NeOnc reports positive Phase 2a data for NEO100 in recurrent IDH1-mutant glioma

Aug 12Regulatory decisionNeonc Technologies, Inc.perillyl alcohol

NeOnc confirms August 12 topline readout for Phase 2a NEO100 glioma study

Aug 10Clinical readoutNEO212 Neonc Technologies, Inc.

July 2026

NeOnc board sees resignation of director, election of CEO's niece as replacement

Jul 2PeopleNeonc Technologies, Inc.